Roivant Sciences Ltd (ROIV) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.

Total Revenue Chart for Roivant Sciences Ltd

Roivant Sciences Ltd (ROIV) revenue for FY2026 was USD 8.3M, a -71.6% change from FY2025. Roivant Sciences Ltd's revenue grew from USD 2.3M in 2019 to USD 8.3M in 2026 (255.4% over 7 years). Earnings per share moved from USD -4.84 in 2019 to USD -1.42 in 2023. Revenue compound annual growth rate: 5-year CAGR of -19.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$25.66B
Implied Share Price
$35.53
Enterprise Value
$22.86B
Revenue (TTM)
$7.53M
EBITDA
-$1.36B
Profit Margin
0.00%
Trailing P/E
—
Forward P/E
0.00
Price/Book (MRQ)
6.29
Price/Sales (TTM)
3407.35
EV/EBITDA
0.74
EV/Revenue
3035.18
Dividend Yield
—
Book Value
$5.86
Free Cash Flow (FY2026)
-$758.56M
Free Cash Flow Yield
-2.96%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.